#Wegovy

Wegovy’s GLP-1 weight loss tablet has been approved in Australia for the first time, expected to lead to a surge in demand for the sought-after peptide which could hit the market by the end of this year.

Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.

From Nypost RSS Feed: Oral Ozempic and Wegovy pills now available for same-day delivery on Amazon

From Independent RSS Feed: Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts

Novo Nordisk CEO Mike Doustdar discusses the drugmaker's Wegovy obesity pill which fueled sales in the first quarter. Novo is "very optimistic" on the medication despite competition from Eli Lilly, Doustdar tells Bloomberg Television, and the firm doesn't…

From Independent RSS Feed: Wegovy maker Novo Nordisk boosted by successful weight loss pill launch

Novo Nordisk raised its outlook for 2026 after a strong performance from its newly launched Wegovy pill.

Novo Nordisk said this year’s declines won’t be as bad as initially expected thanks to the new Wegovy pill, which helped fuel sales in the first quarter. For the year, the worst drop for both profit and sales will be 12%, compared with 13% earlier.…

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

Researchers at the University of Utah have discovered an enzyme called Pap B that will chemically change and update drugs like Ozempic and Wegovy making them stronger and last longer.

Hershey’s CEO told stockholders that GLP-1 side effects are creating a ‘strong demand for gum.’

A rare form of vision loss has been linked to certain GLP-1s, but more so to Wegovy than to other weight-loss drugs in this class. Should you worry?

Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, according to an analysis by GoodRx, a drug discount website.

Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version of Wegovy.

Shares in Hims & Hers Health (NYSE: HIMS) are soaring this morning after a report that the telehealth company is entering into a deal with Novo Nordisk A/S (NYSE: NVO) to sell its popular GLP-1 weight-loss drugs, including Wegovy.